More than 50 million people worldwide live with epilepsy, and one‑third of them cannot control their seizures with current medications. Modulight Biotherapeutics is developing a new treatment that uses light to stop seizures exactly when and where they start. The approach uses a light‑sensitive protein (called eOPN3) that works like a precise “off switch” in neurons. A small, implanted device delivers brief pulses of light, which can immediately shut down seizure‑related activity in overactive brain cells.
In this project, the team will build the devices and test the treatment in a large‑animal model of focal, drug‑resistant epilepsy. This work is an important step toward moving the therapy closer to FDA approval.
Related Grants
